Observational study of zevor-cel cell therapy for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study is a real-world observational study that follows people who have already received zevor-cel treatment for their multiple myeloma. It aims to learn more about how well this treatment works in everyday practice and how patients are doing over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have multiple myeloma that has returned or not responded to prior treatments.
- You must have already received the commercial zevor-cel infusion (a cell therapy) as part of your care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of cancer treatment called CAR-T cell therapy for people with multiple myeloma that has relapsed (come back) or is refractory (did not respond to treatment). The treatment uses your own immune cells to attack the cancer. This study is real-world, meaning it happens in everyday clinical practice, not in a strict research setting.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This study follows people with multiple myeloma that has come back or stopped responding to treatment, and looks at how current care is used in real life. It may include people starting talquetamab, and aims to understand outcomes and treatment patterns outside of strict experimental settings.
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
This study follows patients who have had gene-modified T-cell therapy to track their health over time. It does not test a new treatment but helps doctors understand long-term effects.
This trial tests a new gene therapy, LVIVO-TaVec200, for people with multiple myeloma that has returned or not responded to other treatments. The goal is to see if it can help control the cancer.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.